Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats

Suga, Hideiku; Teraoka, Satoshi; K, Ota; Komemushi, Sadao; Furutani, Satoshi; Yamauchi, Shitotomo; Margolin, Solomon B.

doi:10.1016/s0940-2993(11)80261-7

Cited by 102 publications

(89 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The antifibrotic actions of pirfenidone have been shown in several organs, including bleomycin-induced fibrotic lung in hamsters, 26 remnant kidney with collagen accumulation by partial nephrectomy in rats, 27 dimethylnitrosamine-induced fibrotic liver in rats, 28 chlorhexidine gluconate and ethanol-induced sclerosing peritonitis in rats 29 and intimal thickening after angioplasty of the carotid artery in rats. 14 There are a few reports concerning the effect of pirfenidone on heart diseases.…”

Section: Discussionmentioning

confidence: 99%

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

et al. 2011

View full text Add to dashboard Cite

Pirfenidone (5-methyl-1-phenyl-2-[ 1 H]-pyridone) is an effective drug for idiopathic interstitial pneumonia that can prevent and reverse tissue fibrosis in several organs. Therefore, we investigated whether pirfenidone has a potential role in preventing angiotensin II (Ang II)-induced cardiac hypertrophy. A cardiac hypertrophic mouse model was created using an Ang II infusion (200 ng kg À1 min À1 ) in wild-type mice for 2 weeks. Mice were divided into the following three groups: a saline-infused (control) group, an Ang II infusion (vehicle) group and an Ang II infusion+pirfenidone-treated (PFD) group, which received pirfenidone (300 mg kg À1 per day) by gastric gavage during the Ang II infusion. At 2 weeks, we assessed hemodynamics and cardiac function and investigated tissue fibrosis of the myocardium histologically and genetically. Blood pressure in the vehicle group was significantly increased compared to the control group. Although blood pressure was not different between the vehicle and PFD groups, heart weight was significantly decreased in the PFD group. Echocardiography revealed that left ventricular hypertrophy was significantly increased in the vehicle group vs. the control group. Interestingly, pirfenidone significantly inhibited this effect. Continuous infusion of Ang II increased the perivascular and interstitial tissue fibrosis, and pirfenidone inhibited these fibrotic changes. Pirfenidone also inhibited Ang II-induced hypertrophy. In the vehicle group, the mRNA expressions of atrial natriuretic peptide, brain natriuretic peptide and transforming growth factor-b1 were increased, which was significantly inhibited by pirfenidone. Furthermore, the expression of mineralocorticoid receptors was attenuated by pirfenidone. These results indicate that pirfenidone might be effective as an antifibrotic drug in the treatment of cardiac hypertrophy induced by hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Pirfenidone [5-methyl-1-phenyl-2-(1H)-pyridone], an antifibrotic agent, inhibits bleomycin-induced pulmonary fibrosis in hamsters as well as experimental peritonitis in rats (18,41). Recently, pirfenidone has been shown to down-regulate production of intercellular adhesion molecule-1 in IL-1␣-treated human synovial fibroblasts and to inhibit transforming growth factor-␤ at the transcription level in lung tissue from bleomycin-treated mice (17,20).…”

mentioning

confidence: 99%

Pirfenidone Blocks the In Vitro and In Vivo Effects of Staphylococcal Enterotoxin B

Hale

Margolin²,

Krakauer

et al. 2002

Infect Immun

Self Cite

View full text Add to dashboard Cite

Pirfenidone [5-methyl-1-phenyl-2-(1H)-pyridone] down-regulates expression of cytokines and other mediators involved in the onset and development of pulmonary fibrosis. Pirfenidone also inhibits production of tumor necrosis factor alpha (TNF-␣) from macrophages incubated with endotoxin and protects mice against endotoxin shock. Pirfenidone's ability to reduce cytokine expression in these disorders led us to investigate the drug's effect on another cytokine anomaly, superantigen-induced shock. BALB/c mice were exposed to staphylococcal enterotoxin B (SEB) either systemically or by aerosol and subsequently potentiated with a sublethal dose of lipopolysaccharide. In these experiments, pirfenidone given 2 to 4.25 h after SEB resulted in 80 to 100% survival versus only 0 to 10% survival among untreated control animals. Relative to serum cytokine levels from controls given toxin but no drug, there was a 35 to 80% decrease in TNF-␣, interleukin 1, and other proinflammatory cytokines. In vitro experiments with human peripheral blood lymphocytes revealed that pirfenidone reduced SEB-induced cytokine levels 50 to 80% and inhibited 95% of SEB-induced T-cell proliferation. Overall, these studies demonstrated the potential utility of pirfenidone as a therapeutic against septic shock and the biological effects of SEB.

show abstract

“…These results suggest that the RD-10/FD-2000 ratio can be used to detect functional changes in the peritoneum before morphological changes occur. CG is also known to cause peritoneal injury 19) and is frequently used to prepare animal models of peritoneal injury. The RD-10/FD-2000 ratio in rats treated with CG for 1 d was also significantly decreased to about 90% (Fig.…”

Section: Discussionmentioning

confidence: 99%

Evaluation for Peritoneal Injury at an Early Stage Using Dual Macromolecular Markers

Hirata

Fumoto

Miyamoto

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Long-term peritoneal dialysis (PD) frequently produces morphological and functional changes of the peritoneum, making continuation of PD difficult. Therefore, it is necessary to evaluate peritoneal injury at an early stage and develop appropriate therapies. The aims of the present study were to evaluate peritoneal injury at an early stage and assess a drug for prevention of peritoneal injury using our previously developed novel evaluation method.

show abstract

Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats

Cited by 102 publications

References 0 publications

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice

Pirfenidone Blocks the In Vitro and In Vivo Effects of Staphylococcal Enterotoxin B

Evaluation for Peritoneal Injury at an Early Stage Using Dual Macromolecular Markers

Contact Info

Product

Resources

About